NSE: NATCOPHARM | BSE: 524816

Mid-range Performer

Download real time

935.40 2.85 (0.31%)

High vol.+gain this week

NSE 03 Dec, 2025 3:58 PM (IST)

16,753.9

Market Cap

High in industry

Beta 1Year

Very High Volatility

Natco Pharma Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for NATCOPHARM, BSE:524816 Natco Pharma Ltd.

Natco Pharma Ltd.

12 Oct 2017

935.40

0.31%

Natcos (partner Mylan) 1st generic approval for gCopaxone 40mg (USD 2.9 bn market; possibility of 180 day exclusivity) and 2nd generic approval for gCopaxone 20mg (USD 700 mn market) demonstrate its R&D; ability to execute on complex generics with intricate chemistry and complex processes

Natco Pharma has gained 12.16% in the last 1 Week

Natco Pharma Ltd.

09 Aug 2017

935.40

0.31%

Natco Pharmaceuticals Ltd - Result Update Q1FY18

Buy: Natco Pharma Ltd.

Edelweiss

Natco Pharmaceuticals Ltd (NPL) reported a topline of INR 428 crs, which is 5% higher than our estimates. The strong uptick in numbers has been primarily on account of incremental profit...

ICICI Securities Limited downgraded Natco Pharma Ltd. to Sell with a price target of 750.0 on 15 Nov, 2025.

Natco Pharma Ltd.

09 Aug 2017

935.40

0.31%

Natco Pharma Limited

Hold: Natco Pharma Ltd.

Recommendation Target

ICICI Securities Limited

EBITDA margins improved 801 bps YoY to 30.7% (I-direct estimate: 27.5%) mainly due to a favourable product mix. EBITDA grew 77% to | 137 crore (I-direct estimate: | 109 crore) Adjusted net profit increased 96% YoY to | 93 crore (I-direct...

Number of FII/FPI investors decreased from 317 to 235 in Sep 2025 qtr

Natco Pharma Ltd.

08 Aug 2017

935.40

0.31%

Natco Pharma Ltd Q1FY18 results comment

Results Update: Natco Pharma Ltd.

HDFC Securities

Revenue decreased by 25.91% to Rs. 428.1 Cr in Q1FY18 when compared to the previous quarter. Revenue decreased by 25.91% to Rs. 428.1 Cr in Q1FY18 when compared to the previous quarter.

Number of FII/FPI investors decreased from 317 to 235 in Sep 2025 qtr

Natco Pharma Ltd.

09 Jun 2017

935.40

0.31%

Natco Pharmaceuticals Ltd - Price Target Revision

Buy: Natco Pharma Ltd.

Target

Edelweiss

Natco Pharmaceuticals Ltd (NPL) continues to deliver on near-term expectations while simultaneously building up pipeline for a sustainable future growth.

Number of MF schemes decreased from 47 to 19 in Sep 2025 qtr

Natco Pharma Ltd.

07 Jun 2017

935.40

0.31%

Result Update:Natco Pharma

Buy: Natco Pharma Ltd.

Target

Axis Direct

Higher gTamiflu profit share (increased market share and stronger flu season) pushed Q4FY17 EBITDA to Rs 2.4bn, up 159% YoY and 22% above our estimate (despite Rs 600mn one-time expense).

Natco Pharma has lost -33.90% in the last 1 Year

Natco Pharma Ltd.

01 Jun 2017

935.40

0.31%

Natco Pharmaceuticals Ltd - Result Update Q4FY17

Buy: Natco Pharma Ltd.

Target

Edelweiss

Natco Pharmaceuticals Ltd (NPL) reported a topline of INR 577 crs, which was 5% higher than our estimates of INR 550 crs. The strong uptick in numbers was primarily on account of profit...

Natco Pharma has lost -33.90% in the last 1 Year

Natco Pharma Ltd.

31 May 2017

935.40

0.31%

Natco Pharma Limited

Buy: Natco Pharma Ltd.

Target

ICICI Securities Limited

EBITDA margins improved 1810 bps YoY to 41.7% (I-direct estimates: 38.5%) mainly due to Oseltamivir exclusivity. EBITDA grew 159% to | 241 crore (I-direct estimate: | 215 crore) Adjusted net profit increased 178% YoY to | 177 crore (I-direct...

Natco Pharma Ltd. is trading above all available SMAs

Natco Pharma Ltd.

23 Mar 2017

935.40

0.31%

Natco Pharma Ltd - Growth Triggers: Diversification, High-Value Pipeline

Buy: Natco Pharma Ltd.

Edelweiss

Natco Pharmaceuticals (Natco) is a R&D focused player with strong focus on oncology and hepatology. The company is a market leader in the domestic generic oncology space with 23% market share.

Number of MF schemes decreased from 47 to 19 in Sep 2025 qtr

Natco Pharma Ltd.

09 Mar 2017

935.40

0.31%

Initiating Coverage

Buy: Natco Pharma Ltd.

Angel Broking

Natco Pharma is a Hyderabad based pharma company with focus on limited competition and high margin products. It has presence in domestic and global markets and has two main business segments i.e. API and Formulations. Natco's topline and bottomline is set to grow at 36% and 61% CAGR over FY16-FY19E due to 1) strong performance of domestic..

Natco Pharma Ltd. is trading above all available SMAs

Is Natco Pharma Ltd. worth buying?

594 Votes:

Buy 83.0%

Sell 7.41%

Hold 9.6%

RESEARCH REPORTS

Sell SEE REPORTS >

pdf

Hold SEE REPORTS >

pdf